ATC Group: L01XA Platinum compounds

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L01XA in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L01 Antineoplastic agents
3 L01X Other antineoplastic agents
4 L01XA Platinum compounds

Group L01XA contents

Code Title
L01XA01 Cisplatin
L01XA02 Carboplatin
L01XA03 Oxaliplatin
L01XA04 Satraplatin
L01XA05

Active ingredients in L01XA

Active Ingredient Description
Carboplatin

Carboplatin interferes with DNA intrastrand and interstrand crosslinks in cells exposed to the drug. DNA reactivity has been correlated with cytotoxicity.

Cis-Diaminedichloroplatinum

Cisplatin is an anorganic substance containing a heavy metal [cis-diamminedichloroplatinum(II)]. This substance inhibits the DNA synthesis by realising transverse connections within and between the DNA strings. The protein and RNA synthesis is inhibited to a lesser extent.

Oxaliplatin

Oxaliplatin is an antineoplastic active substance belonging to a new class of platinum-based compounds in which the platinum atom is complexed with 1,2-diaminocyclohexane (“DACH”) and an oxalate group.

Satraplatin

Satraplatin is a cytotoxic agent. The primary cytotoxic mechanism of satraplatin is similar to that of other platinum compounds including cisplatin, carboplatin and oxaliplatin, and is based on the formation of DNA adducts. Platinum-DNA adducts, which are formed following uptake of the drug into the nucleus of the cell, activate several cellular processes that mediate the cytotoxicity of these drugs. These processes include the signalling of DNA damage, cell cycle checkpoints and arrest, DNA repair and cell death.

Related product monographs

Title Information Source Document Type  
CARBOPLATIN Solution for infusion Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
CISPLATIN Concentrate for solution for infusion Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
KEMOCARB Concentrate for solution for infusion Health Sciences Authority (SG) MPI, Generic
OXALIPLATIN Concentrate for solution Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC